B cell activation and differentiation yields plasma cells with high affinity antibodies to a given
antigen in a time-frame that allows for host protection. Although the end product is most …

Microarray analyses and gene targeting have recently enhanced the understanding of
factors involved in normal plasma cells and multiple myeloma. Plasma cells develop from …

Over the past 4 decades, basic research has provided crucial information regarding the
cellular and molecular biology of cancer. In particular, the relevance of cancer …

Multiple myeloma (MM) is a treatable, but incurable, malignancy of plasma cells (PC) in the
bone marrow (BM). It represents the final stage in a continuum of PC dyscrasias and is …

Multiple myeloma is a neoplasm of terminally differentiated B cells (plasma cells) in which
chromosome translocations frequently place oncogenes under the control of …

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma
cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of …

Multiple myeloma (MM) is a neoplasm of post–germinal center, terminally differentiated B
cells. It is characterized by a multifocal proliferation of clonal, long-lived plasma cells within …

Multiple myeloma (MM), one of the most intractable malignancies, is characterized by the
infiltration and growth of plasma cells, the most differentiated cells in the B-cell lineage, in …

All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal
gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). Genetic …

Background: Multiple myeloma is the second most common hematologic malignancy, which
to date remains incurable despite advances in treatment strategies including the use of …